ATE496911T3 - Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten - Google Patents

Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten Download PDF

Info

Publication number
ATE496911T3
ATE496911T3 AT06732069T AT06732069T ATE496911T3 AT E496911 T3 ATE496911 T3 AT E496911T3 AT 06732069 T AT06732069 T AT 06732069T AT 06732069 T AT06732069 T AT 06732069T AT E496911 T3 ATE496911 T3 AT E496911T3
Authority
AT
Austria
Prior art keywords
treatment
mental illness
piperazine substituted
substituted benzothiophenes
benzothiophenes
Prior art date
Application number
AT06732069T
Other languages
English (en)
Inventor
Hiroshi Yamashita
Jun Matsubara
Kunio Oshima
Hideaki Kuroda
Nobuaki Ito
Shin Miyamura
Satoshi Shimizu
Tatsuyoshi Tanaka
Haruka Takahashi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE496911(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of ATE496911T3 publication Critical patent/ATE496911T3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT06732069T 2005-04-14 2006-04-12 Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten ATE496911T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005116698 2005-04-14
PCT/JP2006/308162 WO2006112464A1 (en) 2005-04-14 2006-04-12 Piperazine-substituted benzothiophenes for treatment of mental disorders

Publications (1)

Publication Number Publication Date
ATE496911T3 true ATE496911T3 (de) 2011-02-15

Family

ID=36645750

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06732069T ATE496911T3 (de) 2005-04-14 2006-04-12 Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten

Country Status (27)

Country Link
US (14) US7888362B2 (de)
EP (1) EP1869025B3 (de)
KR (1) KR100937623B1 (de)
CN (1) CN101155804B (de)
AR (1) AR053577A1 (de)
AT (1) ATE496911T3 (de)
AU (1) AU2006237905C1 (de)
BR (1) BRPI0609785B8 (de)
CA (1) CA2602247C (de)
CY (2) CY1111206T1 (de)
DE (1) DE602006019838D1 (de)
DK (1) DK1869025T6 (de)
ES (1) ES2358631T7 (de)
HK (1) HK1112236A1 (de)
HU (2) HUE011611T6 (de)
IL (1) IL185909A (de)
IN (1) IN2012DN00855A (de)
LT (1) LTC1869025I2 (de)
LU (1) LUC00086I2 (de)
MY (1) MY142746A (de)
NL (1) NL300946I2 (de)
PL (1) PL1869025T6 (de)
PT (1) PT1869025E (de)
SI (1) SI1869025T1 (de)
TW (1) TWI320783B (de)
WO (1) WO2006112464A1 (de)
ZA (1) ZA200708686B (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
MX2008014622A (es) 2006-05-18 2008-11-28 Arena Pharm Inc Formas cristalinas y procesos para la preparacion de fenil-pirazoles utiles como moduladores del receptor de serotonina 5-ht2a.
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
WO2008047883A1 (en) * 2006-10-13 2008-04-24 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
WO2009101018A2 (en) * 2008-02-15 2009-08-20 F. Hoffmann-La Roche Ag 3-alkyl-piperazine derivatives and uses thereof
JP5404652B2 (ja) 2008-02-22 2014-02-05 アクテリオン ファーマシューティカルズ リミテッド オキサゾリジノン誘導体
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
HUE036506T2 (hu) 2008-10-28 2018-07-30 Arena Pharm Inc 5-HT2A szerotonin receptor modulátort tartalmazó készítmények az ilyen receptor modulátorokkal kapcsolatos rendellenességek kezelésére
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CA2766088C (en) 2009-06-25 2017-06-13 Alkermes, Inc. Heterocyclic compounds for the treatment of neurological and psychological disorders
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
JP5857040B2 (ja) 2010-05-04 2016-02-10 アルカーメス ファーマ アイルランド リミテッド 酸化ラクタム化合物の合成方法
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JOP20120083B1 (ar) 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
TWI546299B (zh) * 2011-07-28 2016-08-21 大塚製藥股份有限公司 用於製造苯并［ｂ］噻吩之方法
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
AU2013259551B2 (en) * 2012-05-09 2017-11-02 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
EP2792359A1 (de) * 2013-04-19 2014-10-22 Merz Pharma GmbH & Co. KGaA Behandlung von L-DOPA-induzierter Dyskinesie mit OPC-14523 oder OPC-34712
KR101472916B1 (ko) 2013-06-27 2014-12-16 한국과학기술연구원 모르폴린 또는 피페라진 화합물, 및 도네페질을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물
CN104557896A (zh) 2013-10-18 2015-04-29 沈敬山 布瑞哌唑、其关键中间体及其盐的制备方法
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
TW201625252A (zh) 2014-04-22 2016-07-16 大塚製藥股份有限公司 藥物
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN105461703B (zh) * 2014-12-29 2019-05-17 深圳市泛谷药业股份有限公司 一种brexpiprazole的制备方法
CN105985314A (zh) * 2015-02-05 2016-10-05 苏州旺山旺水生物医药有限公司 布瑞哌唑类似物的制备方法
CN104844586A (zh) * 2015-04-16 2015-08-19 重庆医药工业研究院有限责任公司 一种依匹哌唑无定型物及其制备方法
CN104829588B (zh) * 2015-04-30 2017-03-29 苏州苏旺森生物医药科技有限公司 一种苯并[b]噻吩的制备方法及其中间体
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
JP2018520187A (ja) 2015-07-15 2018-07-26 アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH 神経変性疾患と関連する幻覚の予防および処置のために有用な５−ｈｔ２ａセロトニン受容体のモジュレーターとしてのジアリールおよびアリールヘテロアリール尿素誘導体
CN105061414B (zh) * 2015-07-21 2019-01-01 杭州新博思生物医药有限公司 一锅法制备Brexpiprazole
WO2017025987A1 (en) 2015-08-11 2017-02-16 Mylan Laboratories Limited Process for the preparation of brexpiprazole
EP3150591A1 (de) 2015-10-02 2017-04-05 Crystal Pharma S.A.U Prozess und zwischenprodukte für die herstellung von benzo[b]thiophenverbindungen
CN106749219A (zh) * 2015-11-20 2017-05-31 江苏恩华药业股份有限公司 一种内酰胺类衍生物及其应用
CN105440026A (zh) * 2015-12-04 2016-03-30 上海勋和医药科技有限公司 依匹哌唑的制备方法
CN105461704A (zh) * 2015-12-15 2016-04-06 南京艾德凯腾生物医药有限责任公司 一种依匹哌唑的制备方法
WO2017106641A1 (en) 2015-12-17 2017-06-22 Assia Chemical Industries Ltd. Solid state forms of brexpiprazole
CN106916148B (zh) * 2015-12-25 2021-07-06 上海科胜药物研发有限公司 一种合成依匹哌唑的方法
EP3397636B1 (de) * 2015-12-28 2021-08-04 Honour (R&D) Verfahren zur herstellung von chinolin-2(1h)-on-derivaten
CN106938982A (zh) * 2016-01-05 2017-07-11 连云港皓海医药科技有限公司 布瑞哌唑的制备方法及用于制备布瑞哌唑的化合物
CN105399736B (zh) * 2016-01-07 2018-10-19 安徽省逸欣铭医药科技有限公司 一种依匹哌唑新的制备方法
US10501450B2 (en) 2016-02-01 2019-12-10 Hexal Ag Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
US20170320862A1 (en) 2016-05-03 2017-11-09 Cadila Healthcare Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107365305A (zh) 2016-05-12 2017-11-21 上海奥博生物医药技术有限公司 一种依匹哌唑新晶型及其制备方法
WO2017208251A1 (en) * 2016-05-31 2017-12-07 Cipla Limited A new stable polymorph of brexpiprazole and process for preparation thereof
WO2017216661A1 (en) 2016-06-17 2017-12-21 Jubilant Generics Limited Process for the preparation of brexpiprazole from 7-(4-chlorobutoxy)quinolin-2(1h)-one and 1-(benzo[b]thiophen-4-yl)piperazine
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US11123300B2 (en) 2016-08-16 2021-09-21 Hexal Ag Immediate release tablet of a benzothiophene compound
US20200093821A1 (en) 2016-08-16 2020-03-26 Hexal Ag Pharmaceutical Compositions of a Benzothiophene Compound
WO2018060916A1 (en) * 2016-09-28 2018-04-05 Alembic Pharmaceuticals Limited Process for the preparation of brexpiprazole and intermediates thereof
CN107936005A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种依匹哌唑新晶型ii及其制备方法
US11279696B2 (en) 2016-11-09 2022-03-22 Msn Laboratories Private Limited Processes for the preparation of 7-{4-[4-(1-benzothiophen-4-yl) piperazin-1-yl]butoxy}quinolin-2(1H)-one
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
EP3577111A1 (de) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Kristallines brexpiprazol
WO2018172463A1 (en) 2017-03-22 2018-09-27 Amneal Pharmaceuticals Company Gmbh Process for the preparation of brexpiprazole
WO2019073481A1 (en) * 2017-10-12 2019-04-18 Indoco Remedies Limited PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE AND ITS INTERMEDIATES
KR20200099154A (ko) 2017-12-14 2020-08-21 하. 룬드벡 아크티에셀스카브 1H-피라졸로[4,3-b]피리딘의 투여를 포함하는 조합 치료제
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3501506B1 (de) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische tablettenzusammensetzung mit brexpiprazol
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
EP3545950A1 (de) 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmazeutische zusammensetzung, umfassend brexpiprazole
CN110627777B (zh) * 2018-06-21 2021-01-26 中国科学院上海药物研究所 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
CN111320619A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物的杂质及用途
CN109970705B (zh) * 2019-05-14 2021-02-09 浙江工业大学 一种应用廉价金属铜制备依匹哌唑中间体及依匹哌唑的方法
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
EP4132646A1 (de) * 2020-04-08 2023-02-15 Remix Therapeutics Inc. Verbindungen und verfahren zur modulation des spleissens
WO2022010937A1 (en) * 2020-07-06 2022-01-13 Tactogen Inc Advantageous benzothiophene compositions for mental disorders or enhancement
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114181202A (zh) * 2021-12-17 2022-03-15 湖南省湘中制药有限公司 一种依匹哌唑的制备方法
CN118580229A (zh) * 2024-08-07 2024-09-03 湖南一格制药有限公司 布瑞哌唑的制备方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910955A (en) 1970-12-21 1975-10-07 Aspro Nicholas Ltd Benzothiophene-ethylamines
DK574274A (de) 1973-12-06 1975-07-28 Ciba Geigy Ag
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2960178D1 (en) 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (de) 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
JPS5646812A (en) 1979-09-27 1981-04-28 Otsuka Pharmaceut Co Ltd Central nervous system depressant
JPS5649361A (en) 1979-09-28 1981-05-02 Otsuka Pharmaceut Co Ltd Carbostyril derivative
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS56164186A (en) 1980-05-21 1981-12-17 Otsuka Pharmaceut Co Ltd Carbostyril derivative
IT1201087B (it) 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
ATE81975T1 (de) 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
US4704390A (en) 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
GB8704572D0 (en) 1987-02-26 1987-04-01 Lundbeck & Co As H Organic compounds
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
WO1991000863A1 (en) 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
CA2067475C (en) 1991-05-08 2000-10-10 Yasuo Oshiro Carbostyril derivatives and their use
US5436246A (en) 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
DK148392D0 (da) 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
US5506248A (en) 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
CN1154105A (zh) * 1994-06-08 1997-07-09 H·隆德贝克有限公司 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物
CA2157348A1 (en) 1994-09-01 1996-03-02 Aventis Pharmaceuticals Inc. 3-¬4-(1-substituted-4-piperazinyl)butyl|-4-thiazolidinone and related compounds
US5576321A (en) 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
PT732332E (pt) * 1995-03-17 2002-06-28 Aventis Pharma Inc Benzotienilpiperazinas substituidas sua utilizacao como medicamentos e processos para a sua preparacao
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
NZ318436A (en) 1995-09-15 1999-02-25 Synthelabo Quinolein-2(1h)-one derivatives substituted with a 4-(thieno[3,2-c]pyridin-4-yl)piperazine-1-yl or 4-(4-fluorobenzoyl)piperidin-1-yl group as serotonin antagonists
US5977110A (en) 1995-09-22 1999-11-02 Warner-Lambert Company Substituted cyclohexylamines as central nervous systems agents
WO1997036893A1 (en) 1996-03-29 1997-10-09 Duphar International Research B.V. Piperazine and piperidine compounds
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
WO1998007703A1 (fr) 1996-08-22 1998-02-26 Meiji Seika Kaisha, Ltd. Derives quinoleine et agent psychotrope
FR2761068B1 (fr) 1997-03-20 1999-04-23 Synthelabo Derives de piperazin-4-ylthieno[3,2-c]pyridin-4-yl-2- carboxamide, leur preparation et leur application en therapeutique
ES2128266B1 (es) 1997-07-08 2000-01-16 Vita Invest Sa Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes.
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
DE69815003T2 (de) 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilisierte pharmazeutische Zusammensetzung
ATE225345T1 (de) 1998-06-30 2002-10-15 Lilly Co Eli Auf serotonin-verwandte systeme wirkende piperidin-derivate
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
KR100882544B1 (ko) 1999-05-24 2009-02-12 미쓰비시 타나베 파마 코퍼레이션 페녹시프로필아민 화합물
ATE280169T1 (de) 1999-07-29 2004-11-15 Lilly Co Eli Serotonerge benzothiophene
US6562375B1 (en) 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US6784180B2 (en) 1999-12-20 2004-08-31 Eli Lilly And Company Piperidines derivatives and their use as serotonin receptor antagonists
AR027133A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de heteroarilo, su preparacion y uso.
WO2003030868A1 (en) 2001-10-09 2003-04-17 Bristol-Myers Squibb Company Flashmelt oral dosage formulation
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2188344B1 (es) 2000-11-29 2004-09-16 Laboratorios Vita, S.A. Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002066469A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
JP4310605B2 (ja) 2001-05-25 2009-08-12 大塚製薬株式会社 医薬用組成物
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
DE10151569A1 (de) 2001-10-23 2003-04-30 Basf Ag Thermisch härtbare Bindemittel
AU2002353659A1 (en) 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
AU2003263413A1 (en) 2002-09-17 2004-04-08 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2004029948A1 (de) 2002-09-20 2004-04-08 Osram Opto Semiconductors Gmbh Optischer abtastkopf und verfahren zur herstellung desselben
AU2003260882A1 (en) 2002-09-26 2004-04-19 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
RU2356554C2 (ru) 2002-12-27 2009-05-27 Оцука Фармасьютикал Ко., Лтд. Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
TWI258470B (en) 2003-01-09 2006-07-21 Otsuka Pharma Co Ltd Process for preparing aripiprazole
EP1620437B1 (de) 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
CA2526562C (en) 2003-05-23 2011-06-28 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
GB0504203D0 (en) 2005-03-01 2005-04-06 Novartis Ag Organic compounds
CA2600542A1 (en) 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
UA97349C2 (uk) 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
RU2470635C2 (ru) 2007-05-11 2012-12-27 Сантен Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза
US7968431B2 (en) 2008-07-15 2011-06-28 Taiwan Semiconductor Manufacturing Company, Ltd. Diffusion region routing for narrow scribe-line devices
WO2010052727A1 (en) 2008-11-04 2010-05-14 Ideal Cures Private Limited High performance film coating compositions
TWI546299B (zh) * 2011-07-28 2016-08-21 大塚製藥股份有限公司 用於製造苯并［ｂ］噻吩之方法
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same

Also Published As

Publication number Publication date
US20160051548A1 (en) 2016-02-25
CY1111206T1 (el) 2015-06-11
US20170000786A1 (en) 2017-01-05
US8349840B2 (en) 2013-01-08
HUS1800041I1 (hu) 2018-11-28
EP1869025A1 (de) 2007-12-26
PL1869025T6 (pl) 2017-10-31
LTC1869025I2 (lt) 2019-05-10
EP1869025B3 (de) 2016-08-31
KR20080002817A (ko) 2008-01-04
US20190321359A1 (en) 2019-10-24
HK1112236A1 (en) 2008-08-29
IN2012DN00855A (de) 2015-07-10
AU2006237905C1 (en) 2015-11-19
WO2006112464A1 (en) 2006-10-26
USRE48059E1 (en) 2020-06-23
US7888362B2 (en) 2011-02-15
MY142746A (en) 2010-12-31
US20170231983A1 (en) 2017-08-17
LTPA2018509I1 (lt) 2018-09-10
ZA200708686B (en) 2009-01-28
TW200716619A (en) 2007-05-01
US20200237755A1 (en) 2020-07-30
US8618109B2 (en) 2013-12-31
ES2358631T3 (es) 2011-05-12
US20140163039A1 (en) 2014-06-12
SI1869025T1 (sl) 2011-04-29
AU2006237905A1 (en) 2006-10-26
IL185909A (en) 2014-08-31
CA2602247A1 (en) 2006-10-26
ES2358631T7 (es) 2016-11-17
US9480686B2 (en) 2016-11-01
US20130158044A1 (en) 2013-06-20
CN101155804A (zh) 2008-04-02
TWI320783B (en) 2010-02-21
NL300946I2 (nl) 2018-09-26
BRPI0609785B1 (pt) 2020-10-20
US20190117648A1 (en) 2019-04-25
CA2602247C (en) 2013-04-02
US9206167B2 (en) 2015-12-08
HUE011611T6 (en) 2017-04-28
DK1869025T6 (da) 2017-01-02
US20100179322A1 (en) 2010-07-15
LUC00086I2 (de) 2018-11-26
US9839637B1 (en) 2017-12-12
DE602006019838D1 (de) 2011-03-10
BRPI0609785B8 (pt) 2021-05-25
DK1869025T3 (da) 2011-04-04
BRPI0609785A2 (pt) 2010-04-27
AU2006237905B2 (en) 2009-09-03
PL1869025T3 (pl) 2011-06-30
CY2018028I1 (el) 2019-07-10
EP1869025B1 (de) 2011-01-26
US20210113556A1 (en) 2021-04-22
PT1869025E (pt) 2011-02-04
KR100937623B1 (ko) 2010-01-20
CY2018028I2 (el) 2019-07-10
AR053577A1 (es) 2007-05-09
US20110152286A1 (en) 2011-06-23
US20170368060A1 (en) 2017-12-28
IL185909A0 (en) 2008-01-06
CN101155804B (zh) 2013-03-27
US20180214444A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
ATE496911T3 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE532518T1 (de) Dipeptidyl-peptidase-hemmer zur behandlung von diabetes
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602006010364D1 (de) Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1869025

Country of ref document: EP